Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,marketState,currency,exchange,shortName,market,priceHint,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,exchangeDataDelayedBy,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,industry
t0,GSGTF,11534000,45909900,5211000,,-9967500,,-9968500,2529500,2081000,-5659500,-5659500,,-632500,,,,1000,2081000,7740500,0,-4308000,,-9968500,-9968500,133000,152776000,35694000,11667000,3929000,47361000,1022000,885000,-34015000,2407000,-108116000,315000,37943000,17123000,2405000,-108116000,3154000,43759000,3264000,14119000,7588000,-160000,-641000,-162000,3204000,14741000,1149500,12665000,10556000,131500,-4155000,223000,-26500,-1128000,5108500,-2000,26636000,en-US,US,EQUITY,False,Delayed Quote,PREPRE,USD,PNK,GENSIGHT BIOLOGICS SA,us_market,2,Other OTC,GenSight Biologics S.A.,EUR,561,1463,3.0,0.96774197,3.1 - 11.3,-5.2000003,-0.460177,3.1,11.3,-1.156,0,0.254,8.377505,-2.2775054,-0.27185962,9.513092,-3.4130921,-0.35877842,280050400,24.015747,15,America/New_York,EDT,-14400000,False,False,-32.22222,6.1 - 6.1,9.0,finmb_235063288,6.1,1630527359,-2.9,6.1,6.1,6.1,500,2.49,,,11.3,3.1,8.38,9.51,561,1.46k,45.91M,,35.58M,17.50%,40.93%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-335.13%,-39.03%,-306.65%,7.44M,0.21,70.30%,7.44M,-24.62M,-34.02M,-1.16,,37.94M,0.83,19.13M,163.96,2.56,0.25,-15.04M,-6.46M,Value,75012,Healthcare,25,"GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.",Paris,33 1 76 21 72 20,1609372800,France,http://www.gensight-biologics.com,86400,"74, rue du Faubourg Saint-Antoine",Biotechnology
t-1,GSGTF,11534000,45909900,5211000,,-9967500,,-9968500,2529500,2081000,-5659500,-5659500,,-632500,,,,1000,2081000,7740500,0,-4308000,,-9968500,-9968500,133000,152776000,35694000,11667000,3929000,47361000,1022000,885000,-34015000,2407000,-108116000,315000,37943000,17123000,2405000,-108116000,3154000,43759000,3264000,14119000,7588000,-160000,-641000,-162000,3204000,14741000,1149500,12665000,10556000,131500,-4155000,223000,-26500,-1128000,5108500,-2000,26636000,en-US,US,EQUITY,False,Delayed Quote,PREPRE,USD,PNK,GENSIGHT BIOLOGICS SA,us_market,2,Other OTC,GenSight Biologics S.A.,EUR,561,1463,3.0,0.96774197,3.1 - 11.3,-5.2000003,-0.460177,3.1,11.3,-1.156,0,0.254,8.377505,-2.2775054,-0.27185962,9.513092,-3.4130921,-0.35877842,280050400,24.015747,15,America/New_York,EDT,-14400000,False,False,-32.22222,6.1 - 6.1,9.0,finmb_235063288,6.1,1630527359,-2.9,6.1,6.1,6.1,500,2.49,,,11.3,3.1,8.38,9.51,561,1.46k,45.91M,,35.58M,17.50%,40.93%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-335.13%,-39.03%,-306.65%,7.44M,0.21,70.30%,7.44M,-24.62M,-34.02M,-1.16,,37.94M,0.83,19.13M,163.96,2.56,0.25,-15.04M,-6.46M,Value,75012,Healthcare,25,"GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.",Paris,33 1 76 21 72 20,1609372800,France,http://www.gensight-biologics.com,86400,"74, rue du Faubourg Saint-Antoine",Biotechnology
t-2,GSGTF,-597000,45909900,5982000,,-7039000,,-7039000,2464500,1639000,-6807500,-6807500,,-226000,,,,0,1639000,8446500,0,-231500,,-7039000,-7039000,144000,128142000,27605000,-453000,541000,27152000,821000,442000,-14078000,423000,-115338000,337000,16831000,13206000,1469000,-115338000,3772000,22899000,3728000,11503000,8745000,-25000,813000,-26000,2296500,2188500,1066500,24500,-1209500,-4500,-3367000,240000,422000,-132500,1130500,-1000,9693000,en-US,US,EQUITY,False,Delayed Quote,PREPRE,USD,PNK,GENSIGHT BIOLOGICS SA,us_market,2,Other OTC,GenSight Biologics S.A.,EUR,561,1463,3.0,0.96774197,3.1 - 11.3,-5.2000003,-0.460177,3.1,11.3,-1.156,0,0.254,8.377505,-2.2775054,-0.27185962,9.513092,-3.4130921,-0.35877842,280050400,24.015747,15,America/New_York,EDT,-14400000,False,False,-32.22222,6.1 - 6.1,9.0,finmb_235063288,6.1,1630527359,-2.9,6.1,6.1,6.1,500,2.49,,,11.3,3.1,8.38,9.51,561,1.46k,45.91M,,35.58M,17.50%,40.93%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-335.13%,-39.03%,-306.65%,7.44M,0.21,70.30%,7.44M,-24.62M,-34.02M,-1.16,,37.94M,0.83,19.13M,163.96,2.56,0.25,-15.04M,-6.46M,Value,75012,Healthcare,25,"GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.",Paris,33 1 76 21 72 20,1609372800,France,http://www.gensight-biologics.com,86400,"74, rue du Faubourg Saint-Antoine",Biotechnology
t-3,GSGTF,-597000,45909900,5982000,,-7039000,,-7039000,2464500,1639000,-6807500,-6807500,,-226000,,,,0,1639000,8446500,0,-231500,,-7039000,-7039000,144000,128142000,27605000,-453000,541000,27152000,821000,442000,-14078000,423000,-115338000,337000,16831000,13206000,1469000,-115338000,3772000,22899000,3728000,11503000,8745000,-25000,813000,-26000,2296500,2188500,1066500,24500,-1209500,-4500,-3367000,240000,422000,-132500,1130500,-1000,9693000,en-US,US,EQUITY,False,Delayed Quote,PREPRE,USD,PNK,GENSIGHT BIOLOGICS SA,us_market,2,Other OTC,GenSight Biologics S.A.,EUR,561,1463,3.0,0.96774197,3.1 - 11.3,-5.2000003,-0.460177,3.1,11.3,-1.156,0,0.254,8.377505,-2.2775054,-0.27185962,9.513092,-3.4130921,-0.35877842,280050400,24.015747,15,America/New_York,EDT,-14400000,False,False,-32.22222,6.1 - 6.1,9.0,finmb_235063288,6.1,1630527359,-2.9,6.1,6.1,6.1,500,2.49,,,11.3,3.1,8.38,9.51,561,1.46k,45.91M,,35.58M,17.50%,40.93%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",0.00%,-335.13%,-39.03%,-306.65%,7.44M,0.21,70.30%,7.44M,-24.62M,-34.02M,-1.16,,37.94M,0.83,19.13M,163.96,2.56,0.25,-15.04M,-6.46M,Value,75012,Healthcare,25,"GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.",Paris,33 1 76 21 72 20,1609372800,France,http://www.gensight-biologics.com,86400,"74, rue du Faubourg Saint-Antoine",Biotechnology
